Covaxin has proved to be up to 81% effective in its Phase III trial

India’s indigenous vaccine ‘Covaxin’ has proved to be up to 81% effective in its Phase III trial against the Corona virus. This information was given by Bharat Biotech, the company that created this vaccine, on Wednesday.

Bharat Biotech reported that Phase III trials of the vaccine were conducted on 25,800 people. The trial conducted with ICMR (Indian Council of Medical Research) is the largest level clinical trial ever conducted in India.

On the other hand, ICMR said that the results of the third phase of the trial were evaluated by an independent data security and monitoring board. In this, it has been found that covaxine is effective against different age groups and different types of SARS cove-2 present in the country.

Dr. Balram Bhargava, Director General of ICMR, said, a fully indigenous Kovid-19 vaccine (Kovaxin) was produced in less than eight months. It shows how ready India is to deal with such challenging situations.

Let us know that the second phase of the vaccination campaign against the corona virus epidemic is going on in India. Two vaccines are being installed in the country, one of which is the Kovaccin and the other is the ‘Kovishield’ of Oxford-AstraZeneca.

Covaxin has proved to be up to 81% effective in its Phase III trial
Covaxin has proved to be up to 81% effective in its Phase III trial

Earlier on Tuesday, several senior leaders and celebrities, including Prime Minister Narendra Modi, had administered vaccine supplements against the corona virus. It is worth mentioning that Narendra Prime Minister Modi himself also took a dose of covacine manufactured in the country.

Leave a Reply

Your email address will not be published. Required fields are marked *